V-01

recombinant SARS-CoV-2 fusion protein vaccine · Livzon Pharmaceutical Group Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for V-01, covering 2023-04-25 to 2023-04-25. Get the full timeline:

Most recent: Clinical Trial Update: Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III [Phase 3]